Loading
Trials often have independent radiologists check whether tumours grew. How often they disagree with the treating doctors is a measure of how trustworthy the result is, and it is rarely published.
Blinded independent central review (BICR) is standard for progression-free survival in registrational trials, and discordance with investigator assessment is common. Regulators see the discordance data; the public usually does not. Requiring publication of the discordance rate, its direction by arm, and the sensitivity analysis in every trial report would let readers assess bias, and would create a dataset on when BICR matters and when it can be dropped to save cost.
Shares Run automated statistics and image checks on every cancer manuscript before review, Trial design, endpoints and cost.
Shares RECIST, Progression-free survival (PFS), Biomarkers are not validated or standardised, Trial design, endpoints and cost.
Shares Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue, Biomarkers are not validated or standardised, Trial design, endpoints and cost.
Shares RECIST, Progression-free survival (PFS), Trial design, endpoints and cost.
Shares Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue, Hazard ratio (HR), Biomarkers are not validated or standardised, Trial design, endpoints and cost.
Shares Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue, Biomarkers are not validated or standardised.
Shares Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue, Biomarkers are not validated or standardised.
Shares Hazard ratio (HR), Progression-free survival (PFS), Trial design, endpoints and cost.